Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Osteoporosis is characterized by micro-architectural deterioration of bone tissue leading to low bone mass and bone fragility, especially in the older age. The condition affects both sexes; however women are more prone to it, especially post-menopause when bone loss is accelerated due to reduced estrogen, which helps protect the bones.

Statistics:

The global and China osteoporosis drugs market is estimated to account for US$ 17.1 Bn in terms of value by the end of 2027.

Global and China Osteoporosis Drugs Market: Drivers

Increasing prevalence of osteoporosis is expected to propel growth of the global and China osteoporosis drugs market over the forecast period. For instance, according to the study, ‘The Prevalence of Osteoporosis in China, a Nationwide, Multicenter DXA Survey’, published in October 2019, in The Journal of Bone and Mineral Research, the age-standardized prevalence of osteoporosis at the spine or hip was 6.46% and 29.13% for men and women aged 50 years and older, respectively. A total of 10.9 million men and 49.3 million women in China were estimated to have osteoporosis.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the United Nations, Department of Economic and Social Affairs, Population Division, the geriatric population in China is expected to reach 246,986 thousands in 2030 from 164,487 thousands in 2019.

Statistics:

North America held dominant position in the global and China osteoporosis drugs market in 2019, accounting for 38.5% share in terms of value, followed by Europe and Asia Pacific, respectively.

Figure 1: Global and China Osteoporosis Drugs Market Share (%) Value, By Region, 2019

Global and China Osteoporosis Drugs  | Coherent Market Insights

Global and China Osteoporosis Drugs Market: Restraints

Adverse effects of osteoporosis drugs are expected to hinder growth of the market. For instance, consumption of alendronate may lead to stomach pain, acid reflux, constipation, diarrhea, upset stomach, nausea, or muscle and joint pain.

Moreover, low awareness and diagnosis of osteoporosis, especially in emerging economies is also expected to limit the market growth.

request-sample

Global and China Osteoporosis Drugs Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 12.7 Bn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 3.8% 2027 Value Projection: US$ 17.1 Bn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
  • Asia Pacific: Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • China
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: North Africa, Central Africa, South Africa
Segments covered:
  • By Drug Type
    • Bisphosphonates: Alendronate, Risedronate, Ibandronate, Zoledronic Acid, Others
    • Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, Rank Ligand (RANKL) Inhibitor.
  • By Route of Administration: Oral, Injectable, Others.
  • By Distribution Channel: Hospitals Pharmacies, Online Pharmacies, Retail Pharmacies.
Companies covered:

Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.

Growth Drivers:
  • Increasing prevalence of osteoporosis disease
  • Approval and launch of new products
Restraints & Challenges:
  • Adverse side effects of the drugs

Global and China Osteoporosis Drugs Market: Opportunities 

R&D in novel therapeutics is expected to offer lucrative growth opportunities for players in the global and China osteoporosis drugs market. For instance, in June 2020, researchers from School of Medicine CHA University, South Korea, reported that Tauroursodeoxycholic acid, the U.S. FDA-approved hydrophilic bile acid for the treatment of chronic cholestatic liver disease, may provide a favorable effect on bones and could be used for the prevention and treatment of osteoporosis.

Moreover, increasing number of smokers is also expected to aid in growth of the market. For instance, according to the World Health Organization, 1.337 billion people smoked tobacco worldwide in 2018.

Statistics:

The global and China osteoporosis drugs market was valued at US$ 12.7 Bn in 2019 and is forecast to reach a value of US$ 17.1 Bn by 2027 at a CAGR of 3.8% between 2020 and 2027.

Figure 2: Global and China Osteoporosis Drugs Market Value (US$ Bn), 2016 – 2027

Global and China Osteoporosis Drugs  | Coherent Market Insights

Market Trends/Key Takeaways

Major organizations are focused on reducing the burden of osteoporosis. For instance, in June 2020, The International Osteoporosis Foundation partnered with Amgen and UCB, a global biopharmaceutical company, in collaboration with the University of Oxford, to support its Capture the Fracture program, which aims to reduce hip and vertebral fractures by 25% by 2025.

Approval and launch of AI-based products to predict osteoporosis is expected to aid in growth of the market. For instance, in May 2020, Zebra Medical Vision received FDA 510(k) clearance for its Vertebral Compression Fractures product, which automatically identifies findings suggestive of compression fractures, which enables clinicians to place patients that are at risk of osteoporosis in treatment pathways.

Global and China Osteoporosis Drugs Market: Competitive Landscape

Major players operating in the global and China osteoporosis drugs market include, Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.

Global and China Osteoporosis Drugs Market: Key Developments

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in May 2020, Teijin Pharma Limited, a partner of Radius Health, Inc., submitted a New Drug Application for abaloparatide-SC in Japan for the treatment of osteoporosis in patients who are at high risk for fractures.

Similarly, in April 2019, Amgen and UCB received the U.S. Food and Drug Administration approval for EVENITY (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

Osteoporosis is characterized by reduction in the density and quality of bones that often result in broken bones in the wrist, hip, and spine. Various factors responsible for osteoporosis include, genetic factors, low intake of calcium, magnesium, and vitamin D, eating disorders such as anorexia, inactivity and immobility, and excessive alcohol intake. Increasing approvals and launches of novel osteoporosis drugs along with increasing prevalence of osteoporasis is expected to significantly drive the osteoporosis treatment market growth over forecast period.

Key features of the study:

  • This report provides in-depth analysis of the Global and China Osteoporosis Drugs Market  and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the Global and China Osteoporosis Drugs Market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The Global and China Osteoporosis Drugs Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global and China Osteoporosis Drugs Market

Detailed Segmentation:

  • Global and China Osteoporosis Drugs Market, By Drug Type:
    • Bisphosphonates
      • Alendronate
      • Risedronate
      • Ibandronate
      • Zoledronic Acid
      • Others
    • Calcitonin
    • Hormone Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Rank Ligand (RANKL) Inhibitor
  • Global and China Osteoporosis Drugs Market, By Route of Administration:
    • Oral
    • Injectable
    • Others
  • Global and China Osteoporosis Drugs Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Global and China Osteoporosis Drugs Market, By Region:
    • North America
      • By Drug Type:
        • Bisphosphonates
          • Alendronate
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin
        • Hormone Therapy
        • Selective Estrogen Receptor Modulators (SERMs)
        • Parathyroid Hormone-Related Protein (PTHrP) Analog
        • Rank Ligand (RANKL) Inhibitor
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospitals Pharmacies
        • Online Pharmacies
        • Retail Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Type:
        • Bisphosphonates
          • Alendronate
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin
        • Hormone Therapy
        • Selective Estrogen Receptor Modulators (SERMs)
        • Parathyroid Hormone-Related Protein (PTHrP) Analog
        • Rank Ligand (RANKL) Inhibitor
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospitals Pharmacies
        • Online Pharmacies
        • Retail Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
        • Bisphosphonates
          • Alendronate
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin
        • Hormone Therapy
        • Selective Estrogen Receptor Modulators (SERMs)
        • Parathyroid Hormone-Related Protein (PTHrP) Analog
        • Rank Ligand (RANKL) Inhibitor
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospitals Pharmacies
        • Online Pharmacies
        • Retail Pharmacies
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type:
        • Bisphosphonates
          • Alendronate
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin
        • Hormone Therapy
        • Selective Estrogen Receptor Modulators (SERMs)
        • Parathyroid Hormone-Related Protein (PTHrP) Analog
        • Rank Ligand (RANKL) Inhibitor
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospitals Pharmacies
        • Online Pharmacies
        • Retail Pharmacies
      • By Country
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • China
      • By Drug Type:
        • Bisphosphonates
          • Alendronate
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin
        • Hormone Therapy
        • Selective Estrogen Receptor Modulators (SERMs)
        • Parathyroid Hormone-Related Protein (PTHrP) Analog
        • Rank Ligand (RANKL) Inhibitor
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospitals Pharmacies
        • Online Pharmacies
        • Retail Pharmacies
    • Middle East
      • By Drug Type:
        • Bisphosphonates
          • Alendronate
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin
        • Hormone Therapy
        • Selective Estrogen Receptor Modulators (SERMs)
        • Parathyroid Hormone-Related Protein (PTHrP) Analog
        • Rank Ligand (RANKL) Inhibitor
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospitals Pharmacies
        • Online Pharmacies
        • Retail Pharmacies
      • By Country
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • Bisphosphonates
          • Alendronate
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin
        • Hormone Therapy
        • Selective Estrogen Receptor Modulators (SERMs)
        • Parathyroid Hormone-Related Protein (PTHrP) Analog
        • Rank Ligand (RANKL) Inhibitor
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospitals Pharmacies
        • Online Pharmacies
        • Retail Pharmacies
      • By Country
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • Merck & Co. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Eli Lilly
    • Procter & Gamble
    • Enzo Biochem, Inc.
    • Sanofi-Aventis
    • Novartis
    • Wyeth
    • Roche.
    • GlaxoSmithKline
    • UCB
    • Amgen
    • BeiGene Co., Ltd.
    • Bone Biologics
    • Teijin Pharma Limited
    • JHL Biotech Inc.
    • Keros Therapeutics
    • Taro Pharmaceuticals Inc.
  •  “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Country
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • PEST Analysis
    • Technological Advancements
    • Regulatory Scenario
    • Mergers and Acquisitions
    • Impact of COVID19 on market
  4. Global and China Osteoporosis Drugs Market, By Drug Type, 2019 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Bisphosphonates
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
        • Alendronate
        • Risedronate
        • Ibandronate
        • Zoledronic Acid
        • Others
    • Calcitonin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Hormone Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Selective Estrogen Receptor Modulators (SERMs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Rank Ligand (RANKL) Inhibitor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
  5. Global and China Osteoporosis Drugs Market, By Route of Administration, 2019 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Injectable
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
  6. Global and China Osteoporosis Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
  7. Global and China Osteoporosis Drugs Market, By Region, 2019 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • Germany
        • U.K.
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • China
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Merck & Co.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Procter & Gamble
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Enzo Biochem, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi-Aventis
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Wyeth
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Roche
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • UCB
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amgen
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BeiGene Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bone Biologics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teijin Pharma Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • JHL Biotech Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Keros Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Taro Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 28 market data tables and 18 figures on “Osteoporosis Drugs Market – Global and China forecast to 2027”.

Frequently Asked Questions

The Global and China Osteoporosis Drugs size was valued at US$ 12.7 billion in 2019 and is estimated to exhibit a CAGR of 3.8% between 2020 and 2027.
Hospitals segment held the major market share in 2019 owing increasing prevalence of osteoporosis is expected to propel growth of the Global and China Osteoporosis Drugs over the forecast period.
Major factor driving the growth of Global and China Osteoporosis Drugs during the forecast period increasing prevalence of osteoporosis, new product launch, and adoption of expansion strategies from major companies.
Major factors hampering the growth of the Global and China Osteoporosis Drugs during the forecast period constitutes of adverse effects of osteoporosis drugs.
North America market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner